Skip to main content
Top
Published in: Investigational New Drugs 4/2013

01-08-2013 | PHASE I STUDIES

A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors

Authors: Thierry Lesimple, Julien Edeline, Timothy J. Carrothers, Frédérique Cvitkovic, Borje Darpo, Jean-Pierre Delord, Hervé Léna, Nicolas Penel, Geoff J. Edwards, Kenneth Law, Jantien Wanders, Allan Kristensen, Larisa Reyderman

Published in: Investigational New Drugs | Issue 4/2013

Login to get access

Summary

Background Several cancer therapies can prolong cardiac repolarization. This study assessed the potential of eribulin to affect cardiac repolarization in patients with advanced solid tumors. Methods In this Phase I, open-label, single-arm study, patients received eribulin mesylate (1.4 mg/m2; Days 1 and 8 of a 21-day cycle). The primary objective was to assess the effect of eribulin on the QTcF pre- and post-infusion; QTcF and QTcNi were compared for ability to remove heart-rate dependence of the QT interval. Relationship between concentration of eribulin and ΔQTc was explored using linear mixed-effects analysis. Secondary objectives explored pharmacokinetics, safety, and tolerability. Results Twenty-six patients were enrolled. QTcNi was more effective than QTcF in correcting for heart-rate dependency of the QT interval. On Day 1, mean ΔQTcNi were ~0 at all timepoints. An apparent time-dependent increase in ΔQTc was observed: on Day 8, changes from baseline were larger and more variable, without clear relation to plasma levels of eribulin. Day 8 predose ΔQTcNi was 5 ms, post-infusion mean values ranged from 2 to 9 ms (largest mean ΔQTcNi at 6 h). No new or unexpected toxicities were reported. Conclusion Eribulin demonstrated an acceptable safety profile and a minor prolongation of QTc not expected to be of clinical concern in oncology patients.
Literature
1.
go back to reference Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086–1095PubMedCrossRef Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086–1095PubMedCrossRef
2.
go back to reference Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003–2011PubMedCrossRef Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003–2011PubMedCrossRef
3.
go back to reference Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331–1337PubMedCrossRef Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331–1337PubMedCrossRef
4.
go back to reference Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto C (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 15:4207–4212PubMedCrossRef Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto C (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 15:4207–4212PubMedCrossRef
5.
go back to reference Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28:3922–3928PubMedCrossRef Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28:3922–3928PubMedCrossRef
6.
go back to reference Tan AR, Rubin EH, Walton DC, Shuster DE, Wong NY, Fang F, Ashworth S, Rosen LS (2009) Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 15:4213–4218PubMedCrossRef Tan AR, Rubin EH, Walton DC, Shuster DE, Wong NY, Fang F, Ashworth S, Rosen LS (2009) Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 15:4213–4218PubMedCrossRef
7.
go back to reference Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O’Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954–2961PubMedCrossRef Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O’Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954–2961PubMedCrossRef
8.
go back to reference Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914–923PubMedCrossRef Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914–923PubMedCrossRef
9.
go back to reference Murphy CG, Seidman AD (2009) Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes. Clin Breast Cancer 9(Suppl 2):S58–S65PubMedCrossRef Murphy CG, Seidman AD (2009) Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes. Clin Breast Cancer 9(Suppl 2):S58–S65PubMedCrossRef
10.
go back to reference Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersboll J, Abadie E, Giuliani R, Pignatti F (2012) The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res 18:4491–4497PubMedCrossRef Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersboll J, Abadie E, Giuliani R, Pignatti F (2012) The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res 18:4491–4497PubMedCrossRef
12.
go back to reference Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362–3371PubMedCrossRef Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362–3371PubMedCrossRef
13.
go back to reference Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609–3615PubMedCrossRef Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609–3615PubMedCrossRef
14.
go back to reference Varterasian M, Meyer M, Fingert H, Radlowski D, Asbury P, Zhou X, Healey D (2003) Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol 21:3378–3379PubMedCrossRef Varterasian M, Meyer M, Fingert H, Radlowski D, Asbury P, Zhou X, Healey D (2003) Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol 21:3378–3379PubMedCrossRef
15.
go back to reference Shah RR (2002) Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 16:147–156PubMedCrossRef Shah RR (2002) Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 16:147–156PubMedCrossRef
16.
go back to reference Shah RR (2002) Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol 16:119–124PubMedCrossRef Shah RR (2002) Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol 16:119–124PubMedCrossRef
17.
go back to reference Tornoe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV (2011) Creation of a knowledge management system for QT analyses. J Clin Pharmacol 51:1035–1042PubMedCrossRef Tornoe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV (2011) Creation of a knowledge management system for QT analyses. J Clin Pharmacol 51:1035–1042PubMedCrossRef
18.
go back to reference International Conference on Harmonisation (2012) International conference on harmonisation E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.ich.org. Accessed 23 January 2012 International Conference on Harmonisation (2012) International conference on harmonisation E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://​www.​ich.​org. Accessed 23 January 2012
19.
go back to reference Jonsson MK, Vos MA, Duker G, Demolombe S, van Veen TA (2010) Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology. Pharmacol Ther 127:9–18PubMedCrossRef Jonsson MK, Vos MA, Duker G, Demolombe S, van Veen TA (2010) Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology. Pharmacol Ther 127:9–18PubMedCrossRef
20.
go back to reference Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N (2009) Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157:827–836PubMedCrossRef Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N (2009) Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157:827–836PubMedCrossRef
21.
go back to reference Mukohara T, Nagai S, Mukai H, Namiki M, Minami H (2011) Eribulin mesylate in patients with refractory cancers: a phase I study. Invest New Drugs 30:1926–1933PubMedCrossRef Mukohara T, Nagai S, Mukai H, Namiki M, Minami H (2011) Eribulin mesylate in patients with refractory cancers: a phase I study. Invest New Drugs 30:1926–1933PubMedCrossRef
22.
go back to reference Darpo B (2010) The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 159:49–57PubMedCrossRef Darpo B (2010) The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 159:49–57PubMedCrossRef
23.
go back to reference Fossa AA, Wisialowski T, Magnano A, Wolfgang E, Winslow R, Gorczyca W, Crimin K, Raunig DL (2005) Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 312:1–11PubMedCrossRef Fossa AA, Wisialowski T, Magnano A, Wolfgang E, Winslow R, Gorczyca W, Crimin K, Raunig DL (2005) Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 312:1–11PubMedCrossRef
24.
go back to reference Fossa AA, Wisialowski T, Crimin K (2006) QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization. J Pharmacol Exp Ther 316:498–506PubMedCrossRef Fossa AA, Wisialowski T, Crimin K (2006) QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization. J Pharmacol Exp Ther 316:498–506PubMedCrossRef
25.
go back to reference Malik M (2001) Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12:411–420PubMedCrossRef Malik M (2001) Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12:411–420PubMedCrossRef
26.
go back to reference Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JH (2012) Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs. doi:10.1007/s10637-012-9829-3 Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JH (2012) Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs. doi:10.​1007/​s10637-012-9829-3
27.
go back to reference Bagnes C, Panchuk PN, Recondo G (2010) Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf 5:93–96PubMedCrossRef Bagnes C, Panchuk PN, Recondo G (2010) Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf 5:93–96PubMedCrossRef
28.
go back to reference Kitagawa K, Kawada K, Morita S, Inada M, Mitsuma A, Sawaki M, Iino S, Inden Y, Murohara T, Imai T, Ando Y (2012) Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol 23:743–747PubMedCrossRef Kitagawa K, Kawada K, Morita S, Inada M, Mitsuma A, Sawaki M, Iino S, Inden Y, Murohara T, Imai T, Ando Y (2012) Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol 23:743–747PubMedCrossRef
Metadata
Title
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors
Authors
Thierry Lesimple
Julien Edeline
Timothy J. Carrothers
Frédérique Cvitkovic
Borje Darpo
Jean-Pierre Delord
Hervé Léna
Nicolas Penel
Geoff J. Edwards
Kenneth Law
Jantien Wanders
Allan Kristensen
Larisa Reyderman
Publication date
01-08-2013
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2013
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-012-9893-8

Other articles of this Issue 4/2013

Investigational New Drugs 4/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine